Macronutrient Feed Composition for Steatohepatitis Model Progression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a lack of an efficient animal model that can accurately reproduce the progression of liver diseases from nonalcoholic steatohepatitis to cirrhosis and liver cancer, hindering the development of therapeutic agents that effectively block hepatic fibrosis and alleviate fibrosis and hepatic fibrosis progression.
Innovation Solution
A feed composition comprising specific proportions of proteins, carbohydrates, and fats (13 to 17%, 38 to 42%, and 43 to 47% of total calories, respectively) is administered to mammals, inducing fatty liver, hepatic fibrosis, and insulin resistance, thereby reproducing the progression of liver diseases from steatohepatitis to cirrhosis and liver cancer.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional diets are used for animal modeling, then the animal model cannot accurately reproduce human liver disease progression, but developing a new feed composition requires extensive research and optimization
Solution Approach 1:
The patent applies parameter changes by systematically adjusting the macronutrient composition parameters of the feed (protein 13-17%, carbohydrate 38-42%, fat 43-47% of total calories) to achieve the desired physiological effect. This quantitative optimization of dietary parameters enables accurate reproduction of human liver disease progression in animal models without requiring complex intervention strategies.
2Reliability
If a therapeutic agent is developed to block hepatic fibrosis, then treatment effectiveness can be improved, but without an efficient animal model, treatment responsiveness cannot be accurately evaluated
Solution Approach 1:
The patent applies preliminary action by first establishing a standardized feed composition that reliably induces liver disease progression before evaluating therapeutic agents. This pre-established disease model provides a consistent baseline for accurately assessing treatment responsiveness, eliminating the need to develop new animal models for each therapeutic evaluation.
3Reliability
If the feed composition contains high fat content to induce steatohepatitis, then liver disease progression can be reproduced, but the animal model may not accurately reflect human disease stages
Solution Approach 1:
The patent applies parameter changes by optimizing not only fat content (43-47% of total calories) but also coordinating protein (13-17%) and carbohydrate (38-42%) levels. This multi-parameter optimization ensures that the animal model accurately reproduces human liver disease progression through all stages from steatohepatitis to cirrhosis and liver cancer, rather than simply inducing fatty liver through high fat alone.
Data Source
AI summary
The present invention relates to a composition for inducing liver disease in a mammal and a mammal with a liver disease induced using the same. The animal model of the present invention has been found to be an excellent animal model in which fatty liver, hepatic fibrosis, and insulin resistance are evenly induced, and which successfully reproduces the progression of a series of severe liver diseases, from hepatitis and excessive fibrogenesis in liver tissue through tissue hardening (cirrhosis) to liver cancer, and reflects the characteristics of each stage with high reliability. Accordingly, the present invention may be useful as a means for developing a therapeutic agent for chronic liver disease as well as studying the molecular and circulatory mechanisms of each stage of liver disease.